Tech Company Financing Transactions
Avammune Therapeutics Funding Round
Avammune Therapeutics closed a Series A funding round on 7/10/2019. Investors included private investors.
Transaction Overview
Company Name
Announced On
7/10/2019
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Philadelphia, PA 19019
USA
Philadelphia, PA 19019
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Avammune Therapeutics is a drug discovery company focused on immuno-oncology and especially the STING pathway. Avammune is developing a multimodal approach to modulate the STING pathway to treat cancer. Our multimodal approach employs a combination of engineered viruses and small molecules.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arun Papaiah
Chief Scientific Officer
Aditya Kulkarni
Founder
Srinivasan Namala
Browse more venture capital transactions:
Prev: 7/10/2019: OncoNano Medicine venture capital transaction
Next: 7/10/2019: Seance venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs